Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Receivables (2016 - 2026)

Ocular Therapeutix has reported Receivables over the past 14 years, most recently at $24.3 million for Q1 2026.

  • For Q1 2026, Receivables fell 3.47% year-over-year to $24.3 million; the TTM value through Mar 2026 reached $24.3 million, down 3.47%, while the annual FY2025 figure was $30.6 million, 5.37% down from the prior year.
  • Receivables for Q1 2026 was $24.3 million at Ocular Therapeutix, down from $30.6 million in the prior quarter.
  • Over five years, Receivables peaked at $32.4 million in Q4 2024 and troughed at $19.8 million in Q3 2022.
  • A 5-year average of $26.1 million and a median of $26.2 million in 2023 define the central range for Receivables.
  • Biggest five-year swings in Receivables: surged 70.25% in 2022 and later decreased 8.98% in 2023.
  • Year by year, Receivables stood at $21.3 million in 2022, then rose by 22.76% to $26.2 million in 2023, then rose by 23.72% to $32.4 million in 2024, then decreased by 5.37% to $30.6 million in 2025, then decreased by 20.56% to $24.3 million in 2026.
  • Business Quant data shows Receivables for OCUL at $24.3 million in Q1 2026, $30.6 million in Q4 2025, and $30.8 million in Q3 2025.